10X Genomics Inc reports results for the quarter ended in June - Earnings Summary

10x Genomics

08/08/2024 22:41

* 10X Genomics Inc  TXG.OQ  reported a quarterly adjusted
loss
of 32 cents​​ per share for the quarter ended in June, higher
than the same quarter last year, when the company reported EPS
of -53 cents.  The mean expectation of eighteen analysts for the
quarter was for a loss of 48 cents per share. Wall Street
expected results to range from -62 cents to -34 cents per share.
    * Revenue rose 4.3% to $153.10 million from a year ago;
analysts
expected $150.09 million. 
    * 10X Genomics Inc's reported EPS for the quarter was a loss
of 32
cents​.
    * The company reported a quarterly loss of $37.9 million.
    * 10X Genomics Inc shares had fallen by 6.8% this
quarter and
lost 67.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.5%
in the last three months.​ 
    * In the last 30 days, three analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 8
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for 10X Genomics Inc
is $25.00 
This summary was machine generated from LSEG data August 8 at
09:41 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.48          -0.32          Beat
 Mar. 31 2024      -0.50          -0.50          Met
 Dec. 31 2023      -0.36          -0.41          Missed
 Sep. 30 2023      -0.46          -0.79          Missed